Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD

Raffaella Ronco; Giovanni Franco; Matteo Monzio Compagnoni; Stefano Aliberti; Fabrizio Luppi; Giovani Corrao; Paola Faverio

doi:10.1183/23120541.00158-2023

Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD

ERJ Open Res. 2023 Jul 31;9(4):00158-2023. doi: 10.1183/23120541.00158-2023. eCollection 2023 Jul.

Authors

Raffaella Ronco^{1

2}, Giovanni Franco³, Matteo Monzio Compagnoni^{1

2}, Stefano Aliberti^{4

5}, Fabrizio Luppi³, Giovani Corrao^{1

2}, Paola Faverio³

Affiliations

¹ National Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy.
² Laboratory of Healthcare Research and Pharmacoepidemiology, Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.
³ School of Medicine and Surgery, University of Milano-Bicocca, Respiratory Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
⁴ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
⁵ IRCCS Humanitas Research Hospital, Respiratory Unit, Milan, Italy.

Abstract

Direct healthcare costs for patients with asthma are less than half (-52%) and for patients with COPD are 41% higher if compared to those of patients with bronchiectasis. The leading expense items in bronchiectasis are hospitalisations and antibiotics. https://bit.ly/3Iq8AUP.